Todays Report: Today, Advisors Asset Management Inc. decides to keep it stake in Bio-Rad Laboratories Inc. (BIO) to the level of $655,000

Today, Advisors Asset Management Inc. decides to keep it stake in Bio-Rad Laboratories Inc. (BIO) to the level of $655,000

Advisors Asset Management Inc. boosted its stake in Bio-Rad Laboratories Inc. (NYSE:BIO) by 444.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,996 shares of the company’s stock after buying an additional 3,262 shares during the period. Advisors Asset Management Inc.’s holdings in Bio-Rad Laboratories were worth $655,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Bio-Rad Laboratories by 3.3% in the first quarter. Geode Capital Management LLC now owns 130,025 shares of the company’s stock valued at $17,777,000 after buying an additional 4,121 shares during the last quarter. Nuveen Asset Management LLC increased its stake in shares of Bio-Rad Laboratories by 6.8% in the first quarter. Nuveen Asset Management LLC now owns 8,704 shares of the company’s stock valued at $1,190,000 after buying an additional 555 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Bio-Rad Laboratories by 3.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 18,887 shares of the company’s stock valued at $2,582,000 after buying an additional 578 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of Bio-Rad Laboratories by 131.9% in the first quarter. Squarepoint Ops LLC now owns 5,169 shares of the company’s stock valued at $707,000 after buying an additional 2,940 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Bio-Rad Laboratories by 4.6% in the second quarter. Fisher Asset Management LLC now owns 281,583 shares of the company’s stock valued at $40,525,000 after buying an additional 12,508 shares during the last quarter. 63.23% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Inc. (NYSE:BIO) traded up 0.37% during mid-day trading on Friday, hitting $172.76. 45,263 shares of the stock traded hands. The stock has a 50-day moving average price of $165.33 and a 200-day moving average price of $153.50. The stock has a market cap of $5.10 billion, a P/E ratio of 51.97 and a beta of 0.88. Bio-Rad Laboratories Inc. has a 12 month low of $122.03 and a 12 month high of $174.02.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Tuesday, November 1st. The company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.11. Bio-Rad Laboratories had a net margin of 4.75% and a return on equity of 3.79%. The company had revenue of $508.75 million for the quarter, compared to the consensus estimate of $480.60 million. During the same period in the prior year, the firm posted $0.59 EPS. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities analysts forecast that Bio-Rad Laboratories Inc. will post $2.77 earnings per share for the current year.

BIO has been the subject of several analyst reports. Jefferies Group raised their price objective on shares of Bio-Rad Laboratories from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, September 7th. CL King initiated coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, October 12th. They issued a “buy” rating and a $180.00 price objective for the company. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 8th.

In other Bio-Rad Laboratories news, VP James R. Stark sold 1,299 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $171.42, for a total value of $222,674.58. The sale was disclosed in a filing with the SEC, which is available through this link. 28.38% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Related posts

Leave a Comment